Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws.
Ultragenyx reported the study results on December 29, 2025. Both studies failed to achieve their primary endpoint of a reduction in annualized clinical fracture rate against placebo in the Orbit study and against biophosphonates, the standard care, in the Cosmic study.
The Phase III studies also failed to correlate the secondary result to a reduction in fracture rate, despite successfully showing an improvement in the tested patients' bone density. Ultragenyx had previously relied on the results Phase II of the Orbit study to claim a causal link between improved bone density and a reduction in annualized fracture rate.
In announcing the results, the company pointed to a "low fracture rate in the placebo group" as a justification for Orbit's failed results. Management had previously highlighted there were no "uncontrolled factors" in the study and they had crafted the study in such a way to "actually increase their fractures, which would give [them] more opportunities to see the difference between [the test groups]."
Analyst coverage following the results turned cautious as analysts quickly began slashing their price targets. Barclays noted it now sees "limited opportunity for drug approval despite some trend of clinical benefit."
If you suffered a loss on your Ultragenyx Pharmaceutical Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281595
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Investigation Underway: Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky Over Securities Law Violations
2026-01-26 12:32 AM EST
Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky
2026-01-26 12:30 AM EST
Ongoing Mereo BioPharma Group plc (MREO) Investigation: Protect Your Rights - Contact Levi & Korsinsky
2026-01-26 12:27 AM EST
Jan 22, 2026
The end of the Section 16 exemption for foreign issuer directors and officers marks a major shift in SEC insider reporting. It introduces faster disclosure timelines and new transparency risks for global IR teams. Beginning March 18, 2026 , directors and officers of Canadian and other foreign private issuers (FPIs) will be required to publicly report insider holdings and transactions under Section 16(a) of the U.S. Securities Exchange Act of 1934. This change, enacted under the Holding...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services